Early detection value of miR-29a in patients with acute myocardial infarction - Report - MDSpire

Early detection value of miR-29a in patients with acute myocardial infarction

  • By

  • Yanqing, Wang

  • Peng, Gao

  • Yawei, Duan

  • Hanqi, Su

  • Haibo, Wu

  • Yuan, Jia

  • Zhang, Yue

  • Jia, Liu

  • Hongxiao, Li

  • 李, 向明

  • Wenjuan, Li

  • Xiaoshuai, Shi

  • Tingting, Liu

  • Teng, Huang

  • Rongpin, Du

  • March 23, 2026

  • 0 min

Share

Clinical Report: Diagnostic Significance of miR-29a in Early Stages of AMI

Overview

This study evaluates the diagnostic potential of serum miR-29a as a biomarker for early myocardial remodeling in acute myocardial infarction (AMI). Elevated miR-29a levels correlate with established markers and enhance diagnostic accuracy when combined with NT-proBNP and sST2.

Background

Early detection of myocardial remodeling is crucial in preventing heart failure following acute myocardial infarction (AMI). Current biomarkers are insufficient for timely diagnosis, highlighting the need for novel markers. MicroRNAs, particularly miR-29a, have shown promise in preclinical studies, warranting investigation in clinical settings.

Data Highlights

ParameterSTEMI PatientsHealthy Controls
Serum miR-29a LevelsSignificantly ElevatedNormal
Highest AUC (miR-29a, NT-proBNP, sST2)0.904-
Specificity97.4%-
Sensitivity76.9%-

Key Findings

  • Serum miR-29a levels were significantly higher in STEMI patients compared to healthy controls.
  • MiR-29a levels correlated positively with sST2 and NT-proBNP, and inversely with left ventricular ejection fraction (LVEF).
  • ROC analysis indicated miR-29a as a promising biomarker for early detection of myocardial remodeling.
  • The combination of miR-29a with NT-proBNP and sST2 improved diagnostic accuracy over individual biomarkers.
  • The triad of miR-29a, NT-proBNP, and sST2 achieved an AUC of 0.904.

Clinical Implications

The findings suggest that serum miR-29a could serve as a valuable biomarker for early detection of myocardial remodeling in AMI patients. Incorporating miR-29a into diagnostic protocols may enhance the identification of patients at risk for heart failure.

Conclusion

Serum miR-29a shows significant potential as a novel biomarker for early myocardial remodeling in AMI, offering insights that could improve patient management and outcomes.

Related Resources & Content

  1. Basic Research in Cardiology, Springer, 2021 -- Exploring Extracellular Vesicle-Derived MicroRNAs: A Comparison of Cardioprotection and Regeneration
  2. The ASCO Post, 2013 -- Elevated Serum miR-1290 May Distinguish Early Pancreatic Cancer
  3. Clinical Research in Cardiology, Springer, 2025 -- Diagnostic and prognostic value of regional wall motion abnormalities in patients with non-ST-elevation myocardial infarction
  4. Basic Research in Cardiology, Springer, 2018 -- Targeting Inflammatory Cells and Their Non-Coding RNAs for Myocardial Infarction Treatment
  5. 2025 Guideline for Acute Coronary Syndromes - Professional Heart Daily | American Heart Association
  6. TYPE Systematic Review, Frontiers, 2024 -- Diagnostic Accuracy for Circulating miR-21 in AMI
  7. Frontiers, 2024 -- Exercise mediates myocardial infarction via non-coding RNAs
  8. 2025 Guideline for Acute Coronary Syndromes - Professional Heart Daily | American Heart Association
  9. TYPE Systematic Review
  10. Frontiers | Exercise mediates myocardial infarction via non-coding RNAs

Original Source(s)

Early detection value of miR-29a in patients with acute myocardial infarction

  • by Yanqing, Wang , Peng, Gao , Yawei, Duan , Hanqi, Su , Haibo, Wu , Yuan, Jia , Zhang, Yue , Jia, Liu , Hongxiao, Li , 李, 向明 , Wenjuan, Li , Xiaoshuai, Shi , Tingting, Liu , Teng, Huang , Rongpin, Du

  • March 23, 2026

Related Content

Effective VA-ECMO Intervention for Severe Cardiotoxicity Induced by Neoadjuvant Paclitaxel and Cisplatin in Laryngeal Cancer: A Case Study

A transformer-based survival model for prediction of all-cause mortality in patients with heart failure: a multi-cohort study

Serial extracellular volume quantification using cardiac magnetic resonance imaging in transthyretin amyloidosis patients treated with tafamidis